Gattex Approved for Short Bowel Syndrome

FRIDAY, Dec. 21 (HealthDay News) -- Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome, which results when the small and/or large intestine are surgically removed.

Extensive removal of the intestines can lead to poor absorption of fluids and nutrients, the FDA said Friday in a news release.

Gattex is a once-daily injection that helps improve intestinal absorption. Two other drugs, somatropin and glutamine, have been FDA-approved to help treat short bowel disorder.

People who take Gattex may be at increased risk of developing colon cancer, intestinal polyps, gallbladder disease, biliary tract disease or pancreatic disease, the agency said.

The drug was evaluated in two clinical studies and two extension studies. The most common side effects reported were abdominal pain, injection site reactions, nausea, headache and upper respiratory tract infection.

Gattex is marketed by NPS Pharmaceuticals, based in Bedminster, N.J.

More information

The U.S. National Library of Medicine has more about short bowel syndrome.

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.